Chegg Inc. News
Cramer's Mad Money Recap 11/29: Omicron, Amazon, Netflix
Jim Cramer reminds investors that the Omicron Covid variant doesn't pose systemic risks to the markets.
Cramer's Mad Money Recap: Avis Budget Group, Bed Bath & Beyond
Jim Cramer's bullish and he says he would be a buyer on any Fed-induced weakness Wednesday.
Dow, S&P, Nasdaq Close at Record Highs Again Amid Strong Earnings
The Dow, S&P 500 and Nasdaq close at all-time highs as investors prepare for the Fed policy meeting while reacting to the latest earnings reports.
5 Top Stock Decliners for Tuesday: Chegg, Dell, Tesla
Chegg, Dell, Tesla, Zillow and Ralph Lauren are five stocks that fell on Tuesday.
Chegg Shares Slump After Revenue Results and Guidance
Chegg forecast revenue of $194 million to $196 million for the fourth quarter, below analysts’ projection of $241.7 million.
Premarket Movers Tuesday - Chegg, Tesla, Under Armour
Stocks moving in premarket trading include Tesla, Chegg, Under Armour, Pfizer and Avis Budget Group.
HubSpot, Twitter, Sonos: Latest Upgrades and Downgrades
TheStreet's weekly guide to upgrades, downgrades and price-target changes includes Estee Lauder, Twitter and Uber.
When the Market's Wrong: Cramer's 'Mad Money' Recap (Tuesday 2/9/21)
Jim Cramer explains how investors can profit from a selloff. You just need a good memory to take advantage of multi-day declines.
Chegg Rises on Earnings Beat and Price-Target Upgrades
Chegg stock traded higher after the educational-tech provider's quarterly earnings and guidance prompted analysts to raise their price targets.
Cool Off: Cramer's 'Mad Money' Recap (Wednesday 9/23/20)
Jim Cramer says some investors are learning a brutal lesson: You lose money a lot faster than you make it. So, appreciate this pullback as an opportunity to learn.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.